Please login to the form below

Not currently logged in
Email:
Password:

ABPI's Stephen Whitehead steps down

Leaves the UK pharma trade body after four years as its CEO

Stephen WhiteheadThe Association of the British Pharmaceutical Industry's (ABPI) Stephen Whitehead has left the organisation after serving as CEO for four years.

Speaking on behalf of the board ABPI president John Kearney said: “We want to thank Stephen for the very significant contribution he has made to the transformation and success of the ABPI.

“We wish Stephen the best for the future.”

Whitehead joined the UK trade body in 2011, taking over from Richard Barker, and brought senior experience from Barclays and Allied Domecq.

Earlier in his career, Whitehead spent ten years at GlaxoSmithKline and Eli Lilly at UK, European and international levels.

Once he moved back to pharma he quickly made an impact at the ABPI and in 2012 picked up Healthcare Communiquétor of the Year at the Communiqué Awards in recognition of his positive impact at the Association.

The ABPI said it would now begin searching for a new CEO and in the meantime Alison Clough would continue as acting CEO.

2nd October 2015

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics